When coordinated to 2-oxobenzoyl- C, O chelating ligands (O⌒C O) (⌒ = 3- tert -butyl-5-methylphenyl, 3,5-di- tert -butylphenyl, 3-methoxyphenyl, 3,4-benzocyclohexenyl, cyclohexenyl), 18 electron nickel(II) complexes Ni(O⌒C O)(PMe 3 ) 3 ( 1 − 5 ) oxidatively add iodomethane affording thermally labile Ni IV compounds trans-mer- Ni(Me)I(O⌒C O)(PMe 3 ) 2 ( 6 − 10 ) or react with iodine in a ligand dismutation reaction to form stable molecules of trans -Ni(O⌒C O) 2 (PMe 3 ) 2 ( 21 − 25 ), which contain cisoidal acylphenolato chelate rings. Acylphenolato compounds 1 − 5 react with larger electrophiles [C 2 H 5 I, (CH 3 ) 2 CHI, n -C 4 H 9 I, cyclo -C 6 H 11 I, CH 3 COCl, PhCOCl, (CH 3 ) 3 COCl] in different regioselectivities affording ketones or esters. The square pyramidal bis[ n -butyl 2-oxophenyl ketone]nickel(II) complex 16 crystallizes in the monoclinic space group C2/c, while the square planar chloro(phenyl)nickel(II) complex 19 with an ester group in the 2-position crystallizes in the triclinic space group P 1̄. Steric control of C,C-coupling reactions is demonstrated in three transformations, starting either from (acylphenolato)nickel(II) or from metastable diorganonickel(IV) compounds.
No takes yet. Share an insight, caveat, or question.
Klein et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: